The diagnostics unit will provide research services for pharma and biotech industry customers developing personalised medicines. Key to this offering is Almac’s unique disease specific array (DSA) technology that can differentiate between various differet types of cancer.
The unit’s operations will be split between the new Craigavon site and the $112m (€78.6m) facility that Almac is building in Durham, North Carolina. The US facility has been under construction since July last year and is due to be operations sometime in 2010.
